Skip to content

Study · Animal study (in vivo) · calf · 1997

7 results

The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I.

Hammon H, Blum JW

The American journal of physiology1 Jul 1997Cited by 58 (Europe PMC)

PMID9252489 (opens in a new tab)DOI10.1152/ajpendo.1997.273.1.e130 (opens in a new tab)PepBankPUB-09252489
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In neonatal calves, plasma Long-R3-IGF-I rose after subcutaneous application.

    In plain wordsIn calves, blood levels of Long-R3-IGF-I rose after it was injected under the skin.

    Peptide
    IGF-1 LR3
    Outcome
    IncreasePlasma Long-R3-IGF-I after subcutaneous dosing
    Study

    calfn: not reported in source

    neonatal calves
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    50 micrograms/kg body weight/day · subcutaneous · 7 daysAs given in this study (calf).

    Source sentences

    Summary
    Plasma Long-R3-IGF-I increased after subcutaneous application
    1 context sentence
    Summary · context
    of Long-R3-IGF-I (administered subcutaneously or orally; 50 micrograms.kg body wt-1.day-1 for 7 days)
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In neonatal calves, plasma Long-R3-IGF-I did not increase after the oral dose.

    In plain wordsIn calves, blood levels of Long-R3-IGF-I did not rise after an oral dose.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changePlasma Long-R3-IGF-I after oral dosing
    Study

    calfn: not reported in source

    neonatal calves
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    50 micrograms/kg body weight/day · oral · 7 daysAs given in this study (calf).

    Source sentences

    Summary
    Plasma Long-R3-IGF-I increased after subcutaneous application but not with the oral dose.
    1 context sentence
    Summary · context
    of Long-R3-IGF-I (administered subcutaneously or orally; 50 micrograms.kg body wt-1.day-1 for 7 days)
  3. 03AnimalAnimal study (in vivo)Mechanism

    In neonatal calves, subcutaneous Long-R3-IGF-I lowered native plasma IGF-I.

    In plain wordsIn calves, Long-R3-IGF-I injected under the skin lowered the animal's own IGF-I in blood.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseNative plasma IGF-I
    Study

    calfn: not reported in source

    neonatal calves
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    50 micrograms/kg body weight/day · subcutaneous · 7 daysAs given in this study (calf).

    Source sentences

    Summary
    Native IGF-I was highest in rbGH-injected calves but was lowered by the subcutaneous injection of Long-R3-IGF-I.
    1 context sentence
    Summary · context
    of Long-R3-IGF-I (administered subcutaneously or orally; 50 micrograms.kg body wt-1.day-1 for 7 days)
  4. 04AnimalAnimal study (in vivo)Mechanism

    In neonatal calves, IGF-II concentrations were not modified by any treatment, including Long-R3-IGF-I.

    In plain wordsIn calves, IGF-II levels did not change with any treatment, including Long-R3-IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changePlasma IGF-II
    Study

    calfn: not reported in source

    neonatal calves
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    50 micrograms/kg body weight/day · subcutaneous or oral · 7 daysAs given in this study (calf).

    Source sentences

    Summary
    IGF-II concentrations were not modified by any of the treatments.
    1 context sentence
    Summary · context
    of Long-R3-IGF-I (administered subcutaneously or orally; 50 micrograms.kg body wt-1.day-1 for 7 days)
  5. 05AnimalAnimal study (in vivo)Mechanism

    In neonatal calves, IGFBP-2 increased in calves receiving subcutaneous Long-R3-IGF-I.

    In plain wordsIn calves, IGFBP-2 rose in animals given Long-R3-IGF-I under the skin.

    Peptide
    IGF-1 LR3
    Outcome
    IncreasePlasma IGFBP-2
    Study

    calfn: not reported in source

    neonatal calves
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    50 micrograms/kg body weight/day · subcutaneous · 7 daysAs given in this study (calf).

    Source sentences

    Summary
    IGFBP-2 increased in calves fed only milk replacer and those receiving subcutaneous Long-R3-IGF-I.
    1 context sentence
    Summary · context
    of Long-R3-IGF-I (administered subcutaneously or orally; 50 micrograms.kg body wt-1.day-1 for 7 days)
  6. 06AnimalAnimal study (in vivo)Mechanism

    In neonatal calves, parenteral Long-R3-IGF-I decreased GH concentration.

    In plain wordsIn calves, Long-R3-IGF-I given by injection lowered growth hormone levels in blood.

    Peptide
    IGF-1 LR3
    Outcome
    DecreasePlasma GH concentration
    Study

    calfn: not reported in source

    neonatal calves
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    50 micrograms/kg body weight/day · parenteral · 7 daysAs given in this study (calf).

    Source sentences

    Summary
    Parenteral administration of Long-R3-IGF-I decreased GH concentration but did not affect the secretory pattern.
    1 context sentence
    Summary · context
    of Long-R3-IGF-I (administered subcutaneously or orally; 50 micrograms.kg body wt-1.day-1 for 7 days)
  7. 07AnimalAnimal study (in vivo)Mechanism

    In neonatal calves, parenteral Long-R3-IGF-I did not affect the GH secretory pattern.

    In plain wordsIn calves, Long-R3-IGF-I given by injection did not change the pattern of growth hormone release.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeGH secretory pattern
    Study

    calfn: not reported in source

    neonatal calves
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    50 micrograms/kg body weight/day · parenteral · 7 daysAs given in this study (calf).

    Source sentences

    Summary
    Parenteral administration of Long-R3-IGF-I decreased GH concentration but did not affect the secretory pattern.
    1 context sentence
    Summary · context
    of Long-R3-IGF-I (administered subcutaneously or orally; 50 micrograms.kg body wt-1.day-1 for 7 days)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.